No match scores
Peptide finder
Plate 11
Goal map
Find by outcome
36
Goal pages
1
Record
The short answer
Pick what you want to change. See every compound measured for it in people, most people first. Each one shows what the study found, and the failures are counted. 70 of 453 compounds here have no study in people of any kind.
- Compounds
- 453
- No study in people
- 70
How this ranks
No match scores
Other tools print a match percentage. Nobody measured those numbers. This page shows how many people each goal was measured in, and names the goals nobody has measured in a person.
A thin record in people is usually about who pays for trials. It is not a verdict on the compound.
What users report sits next to the trial count. It is never added into it.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.
Somebody handed you a stack. What is actually known about it?
Add what you are looking at. You get every goal those compounds have been measured for in people. Then you get the longer list of goals they have not.
Mood and anxiety
Does it help anxiety or low mood?
Measured on rating scales, in people who mostly had a diagnosis.
3,092 people · 26 studies in people · 21 compounds
- 01RapastinelPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 2,614 people given it.1,087 people3 studies
A second large trial, two doses instead of one, and the same answer. Six hundred and fifty eight adults with depression got rapastinel at a lower or a higher weekly dose, or a dummy drip. After three weeks all three groups had improved by about the same amount. Neither dose pulled away from the dummy. The company...
ClinicalTrials.gov, Naurex / Allergan, 2016 · 658 people
A third large trial, and a third failure. Four hundred and twenty nine adults with depression got a weekly drip of rapastinel or a dummy. Depression scores fell a little further on the drug after three weeks. The gap was small enough that chance alone routinely produces gaps that size. The company posted the figures...
ClinicalTrials.gov, Naurex / Allergan, 2016 · 429 people
Tested properly in a large trial, and it did not work. Four hundred and sixty five adults with depression got a weekly drip of rapastinel or a dummy on top of their usual antidepressant. After three weeks, depression scores had fallen by the same amount in both groups. If anything the dummy group did slightly better....
ClinicalTrials.gov, Naurex / Allergan, 2016 · number of people not given
- 02HydralazineSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,724 people given it.4 reported1,050 people1 study
In 1,050 Black patients with advanced heart failure, a fixed-dose pill of hydralazine and a nitrate, on top of modern treatment, cut deaths so clearly the trial was stopped early. 6.2% died on the pill against 10.2% on a dummy pill. Again a two-drug pill, in one specific group of people.
The New England Journal of Medicine, 2004 · 1,050 people
- 03DHEAHormoneModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 267 people given it.5 reported168 people2 studies1 found nothing
found nothingThe biggest study of DHEA against a dummy pill as an anti-ageing supplement found nothing that mattered. 144 older men and women with low levels took it for two years. The hormone went up and little else changed. Body shape, strength, fitness, blood sugar control and quality of life did not get better. Bone density...
The New England Journal of Medicine, 2006 · 144 people
In women whose adrenal glands make no DHEA, replacing it helped mood and sexual interest. 24 women took DHEA for four months and a dummy pill for four months. It is a study of people who lack the hormone, not of ageing.
The New England Journal of Medicine, 1999 · 24 people
- 04Melanotan IPeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 170 people given it.8 reported432 people3 studies1 found nothing
A safety study required by European regulators, and the company that sells the drug is all over it. 200 patients were treated and nobody was left untreated, so there is no comparison group. Quality of life scores rose against where patients started, and about nine in ten who began treatment were still on it. Several...
Photodermatology, Photoimmunology and Photomedicine, 2025 · 200 people
found nothingRegulators ordered this follow-up study, and it found real gains in daily life. 117 patients at one hospital were tracked for about two years. On average they gained roughly six more hours outside each week, and their quality of life scores rose. Painful sun reactions still happened as often and lasted as long; they...
JAMA Dermatology, 2020 · 117 people
People with a painful light-intolerance disease felt far better on afamelanotide, but nobody got a dummy implant. 115 patients received just over a thousand implants across up to eight years at clinics in Rome and Zurich. Their quality of life scores started at about a third of the best possible and rose to roughly...
British Journal of Dermatology, 2015 · 115 people
- 05Semax / SelankBlendModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 172 people given it.9 reported62 people1 study
Selank calmed anxiety about as well as a standard sedative did. Sixty two people with long running anxiety or exhaustion were split by chance between Selank and medazepam, a drug in the same family as valium. Both groups improved by a similar amount, and the Selank group was also described as less tired and more...
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people
- 06Semax with selank and dihexaBlendLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 62 people given it.7 reported62 people1 study
Selank calmed anxiety about as well as an older anti-anxiety drug, in a small Russian study. 62 patients with long-running anxiety or nervous exhaustion were treated, 30 with selank and 32 with medazepam. They were rated on standard anxiety scales. The two drugs came out about the same, and selank also lifted energy...
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people
- 07DSIP with selank and epitalonBlendLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 62 people given it.6 reported62 people1 study
Selank eased anxiety about as well as an older anti-anxiety drug, in a small Russian study. 62 patients were treated, 30 on selank and 32 on medazepam, with similar results on standard anxiety scales. One detail matters in a product sold for sleep. Selank also acted as a mild stimulant in that study, lifting energy...
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people
- 08InulinSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 39 people given it.6 reported39 people1 study
Inulin made constipation better, in a small test that ran into a design problem. 39 adults with long-running constipation took 12 g of chicory inulin daily for four weeks and a dummy for four more. Each person tried both in turn without knowing which. Bowel frequency, belly symptoms and quality of life all improved on...
BMC Gastroenterology, 2025 · 39 people
- 09SemaxPeptideModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 354 people given it.9 reported27 people1 study
Semax was measured against a nerve test and it did nothing. Twenty seven people with motor neuron disease took semax up the nose for two ten day courses. Their nerve and muscle testing did not change, and neither did the clinical ratings of their disease. The only score that moved was how they rated their own quality...
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2007 · 27 people
- 10MelittinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 658 people given it.4 reported26 people1 study
Bee sting therapy failed on every measure it was tested on. Twenty six people with relapsing multiple sclerosis were stung up to twenty times a session, three times a week, for six months. Brain scans showed no fewer new lesions. Relapses, disability, fatigue and quality of life were all unchanged. Nobody was...
Neurology, 2005 · 26 people
- 11Neuropeptide YPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 20 people given it.5 reported20 people1 study1 found nothing
found nothingThe only time neuropeptide Y itself has been given to people was a first safety look, not an answer. Twenty six people with PTSD sprayed either the peptide or a dummy up the nose, then swapped a week later, and nobody involved knew the order. Twenty four finished both days. Even the highest dose caused no trouble. One...
International Journal of Neuropsychopharmacology, 2018 · 20 people
- 12SermorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 139 people given it.8 reported19 people1 study1 found nothing
found nothingThe hormone response faded while the injections carried on. Nineteen adults aged 55 to 71 injected salt water nightly for a month, then a sermorelin-like peptide for four more months. Growth hormone and its main blood marker rose within two weeks, stayed up for three months, then drifted back to where they started...
Journal of Clinical Endocrinology and Metabolism, 1997 · 19 people
- 13ARA-290PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 5 completed trials, 95 people given it.7 reported9 people1 study
Every objective measure in this small trial stayed flat. Nine people with swelling at the centre of the retina injected cibinetide daily for three months, and eight finished. Their vision did not improve. Neither did retinal thickness, retinal sensitivity or tear production. The only thing that rose was how they rated...
Journal of Clinical Medicine, 2020 · 9 people
- 14DSIPPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 6 completed trials, 7 people given it.8 reportednumber of people not given1 study
Withdrawal signs eased, and the study cannot prove the drug did it. 107 hospital patients in Geneva coming off alcohol or opioids got vein injections up to six times a day. Most of those assessed had a clear drop in visible signs: racing heart, tremor, sweating and watering eyes. Within one to three days of stopping,...
European Neurology, 1984 · number of people not given
- 15NemifitidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 177 people given it.number of people not given1 study
The result here depends on when you look and who you count. Eighty one adults with depression got a shot of nemifitide at one of two strengths, or a dummy, on weekdays for two weeks. The higher dose beat the dummy at one chosen moment, a week after the shots had stopped. It separated from the dummy only among the more...
International Journal of Neuropsychopharmacology, 2006 · number of people not given
- 16NicotinamideSupplementModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 591 people given it.2 reportednumber of people not given1 study1 found nothing
found nothingThe same team tried to repeat the skin cancer result in transplant patients and it did not work. 158 organ transplant recipients who already had repeated skin cancers took the same dose for a year. New cancers came up 207 times on the vitamin and 210 times on the dummy pill, which is no difference at all. Nothing...
New England Journal of Medicine, 2023 · number of people not given
- 17Kisspeptin-54PeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 122 people given it.8 reportednumber of people not given1 study1 found nothing
found nothingKisspeptin did not touch anxiety. People were given either kisspeptin or a dummy, and their reproductive hormones rose just as expected. Their anxiety did not change at all. This is about the only study in the whole kisspeptin field that measured something psychological rather than a hormone level, and the answer it...
The Journal of Clinical Endocrinology and Metabolism, 2025 · number of people not given
- 18PT-141 with oxytocinBlendLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 10 people given it.6 reportednumber of people not given1 study
Oxytocin was tested properly for sex problems in women, and it did not beat a dummy spray. Thirty women used an oxytocin nasal spray or a dummy spray before sex. Each tried both over 22 weeks, and nobody knew which was which. Sexual function scores rose 26% on oxytocin and 31% on the dummy. Distress about sex fell 36%...
Fertility and Sterility, 2015 · number of people not given
- 19ErythropoietinBiologicStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 4,641 people given it.6 reportednumber of people not given1 study
Pushing blood counts up to normal in kidney disease harmed people. 1,432 adults with long-term kidney disease were treated towards either a high or a lower blood count target, for about 16 months. Deaths, heart attacks, heart failure hospital stays and strokes were more common in the high target group, 125 events...
New England Journal of Medicine, 2006 · number of people not given
- 20Kisspeptin-10PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 4 completed trials, 44 people given it.8 reported29 people1 study
Kisspeptin-54 changed how men's brains responded to sexual and romantic images, and lifted low mood slightly. Twenty-nine healthy men were scanned after receiving the peptide or a dummy. Emotional areas of the brain reacted more strongly to the images on the peptide. This is a brain scan signal and a mood...
Journal of Clinical Investigation, 2017 · 29 people
- 21TestosteroneHormoneModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 5,246 people given it.10 reportednumber of people not given1 study1 found nothing
found nothingTestosterone helped older men with sex and did much less for everything else. It raised their levels to what a man in his twenties or thirties would have. Sex drive, sexual activity and erections all clearly got better. Energy did not get better at all. Walking distance only improved when three studies were lumped...
New England Journal of Medicine, 2016 · number of people not given
- 22SelankPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 192 people given it.8 reportednumber of people not given0 studies
- 23HCGBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 55 people given it.8 reportednumber of people not given0 studies
- 24Vitamin B12SupplementLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.4 reportednumber of people not given0 studies
How this is counted
Studies in people only. Animal and lab work never goes into this ranking, because your question was about a person.
A compound is listed for a goal only when a study on its own page names that goal and reports a result for it. Just naming it is not enough. Say a paper measures testosterone but reports a result about something else. That does not count as testosterone evidence. This tool made that mistake on its first run, and it no longer does.
People counts come from the study lines themselves, and when in doubt they count low. If a line gives no number, the study still counts as a study but adds nobody to the people count. Counts are never added up across compounds, because the same person can be in more than one trial.
The order is by how many people were measured. That is a fact about the evidence, not a judgement about the compound. It is the only order this site will defend. A compound at the top of a list is the most studied. That is not the same as the best.
Nothing here is advice. Nothing here tells you to take anything.